Abel Hall LLC
HRTX icon

Abel Hall LLC’s Heron Therapeutics HRTX Stock Holding History

Abel Hall LLC’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-213,185
Closed -$91K – 968
2026
Q2 		$91K Buy
213,185
+196,278
+1,161% +$157K 0.02% 850
2026
Q1 		$13.5K Sell
16,907
-29,269
-63% -$33.9K ﹤0.01% 798
2025
Q4 		$60K Buy
+46,176
New +$57K 0.01% 643

Other funds holding HRTX

Congress Park Capital
Congress Park Capital Saratoga Springs, New York $381M AUM 20.14% 1-Year Est. Return
Apeiron RIA
Apeiron RIA Dallas, Texas $440M AUM 15.34% 1-Year Est. Return
Redwood Family Wealth
Redwood Family Wealth Addison, Texas $113M AUM 24.54% 1-Year Est. Return
DLK Investment Management
DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return
New Harbor Financial Group
New Harbor Financial Group Worcester, Massachusetts $669M AUM 22.9% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
DI
DDFG Inc Thousand Oaks, California $508M AUM 11.76% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
PAS
PKS Advisory Services Albany, New York $624M AUM 15.91% 1-Year Est. Return

Abel Hall LLC's HRTX Position: Q3 2026 in Review

Abel Hall LLC sold out of Heron Therapeutics (HRTX) in Q3 2026, closing a stake of 213,185 shares — an estimated $91K sold.

Abel Hall LLC first reported a position in HRTX in Q4 2025 and held it in 3 quarters. The position peaked at $91K in Q2 2026. 32 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

  • Abel Hall LLC reported no remaining Heron Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Abel Hall LLC sold 213,185 Heron Therapeutics shares in Q3 2026, an estimated $91K.
  • Abel Hall LLC first reported a position in Heron Therapeutics in Q4 2025 and held it in 3 quarters.
  • Abel Hall LLC's Heron Therapeutics position peaked at $91K in Q2 2026.
  • 32 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.